The lectin pathway (LP) of the complement system may initiate inflammatory reactions when body tissue is altered. We aimed to investigate the levels of the LP proteins in out-of-hospital cardiac arrest patients, and to compare these with healthy individuals. Furthermore, we aimed to clarify whether the duration of targeted temperature management influenced LP protein levels, and we further examined whether LP proteins were associated with 30-day mortality. We included 82 patients resuscitated from out-of-hospital cardiac arrest. The patients were randomly assigned to 24 or 48 hours of targeted temperature management at 33 ± 1°C. Blood samples were obtained 22, 46 and 70 hours after target temperature was reached. Levels of the LP proteins (mannan-binding lectin higher, whereas M-ficolin levels were significantly lower in cardiac arrest patients compared with healthy individuals. MASP-2, MASP-3 and M-ficolin levels changed significantly when comparing 24 and 48 hours of targeted temperature management. The LP protein levels were not different between 30-day survivors and non-survivors after cardiac arrest. The differences in LP protein levels between patients and healthy individuals may indicate that cardiac arrest patients have an activated LP. Overall, the LP protein levels were not influenced by the duration of targeted temperature management, and the levels were not associated with 30-day mortality.
The complement system is important in the generation of inflammation, 11 and it is involved in ischemia-reperfusion injuries. 12 This system is activated during cardiac arrest and after resuscitation, 13 and is suggested to be associated with increased mortality after cardiac arrest. 14 The complement system can be activated through the classical, the alternative, and the lectin pathway (LP). 15 Involvement of the LP in ischemia-reperfusion injuries was first described by Collard et al 16 in 2000. The LP consists of several proteins with different biological functions. 11 Mannan-binding lectin (MBL) and MBL-associated protein of 44 kDa (MAp44) have not previously been associated with higher mortality after cardiac arrest, 17 but other important proteins of the LP have not been investigated. The aim of this study was first to investigate the levels of LP proteins in patients resuscitated from out-of-hospital cardiac arrest, and to compare these with healthy individuals. Second, we aimed to investigate whether the duration of targeted temperature management influenced the levels of LP proteins, and third to examine whether LP proteins were associated with 30-day mortality after out-of-hospital cardiac arrest.
| MATERIALS AND METHODS

| Study design
This study was carried out as a randomized, assessor blinded, single centre study including 82 patients resuscitated from out-of-hospital cardiac arrest. It is an independent sub-study of the trial entitled, "Time-differentiated targeted temperature management after out-of-hospital cardiac arrest". 18, 19 Patient inclusion was performed at the Intensive Care Unit, Aarhus University Hospital, Denmark from February 2013 to May 2015. Patients were randomized 1:1 to standard duration of targeted temperature management (24 hours) or prolonged targeted temperature management (48 hours) at 33 ± 1°C (Figure 1 ). Informed consent was collected from the patients' next of kin, the general practitioner/or the medical public health doctor and the patient, if he/she became capable of giving informed consent. The present study was approved by the Central Denmark Region Committees on Health Research Ethics (journal number 20110022), by The Danish Data Protection Agency (case number 1-16-02-586-15) and was carried out in agreement with The Helsinki Declaration. This study was registered at Clinical Trials (NCT02826057).
Patients were eligible for inclusion if they were between 18 and 80 years of age, were resuscitated from out-of-hospital cardiac arrest of presumed cardiac cause and remained unconscious (Glasgow Coma Score < 8) after sustained return of spontaneous circulation. The exclusion criteria have previously been described in details. 18, 19 norepinephrine was the vasopressor of choice. Patients were rewarmed at a rate of 0.5°C pr. hour after termination of targeted temperature management.
| Blood sampling
Blood samples for LP protein measurement were collected 22 ± 2 hours, 46 ± 2 hours and 70 ± 2 hours after reaching the target temperature ( Figure 1 ). Each blood sample was collected in a 5.0 ml EDTA + gel tube and kept on ice. Shortly thereafter, the samples were centrifuged with 3000 rotations per minute (1880 g) at 4°C for 10 minutes. Plasma was then separated and kept in a −80°C freezer until LP protein analyses. Additionally, LP proteins were measured in blood samples from a cohort of 82 healthy individuals, 21 collected from The Blood Bank at Aarhus University Hospital, Denmark. The cohort of healthy individuals was matched with the cardiac arrest cohort by gender. Blood samples for routine biochemistry were collected and analysed at admission and also after 22 ± 2 hours, 46 ± 2 hours and 70 ± 2 hours after reaching the target temperature. Blood haemoglobin, leukocyte count and platelet count were measured using XE-5000 haematology analyser (Sysmex, Kobe, Japan). Plasma creatinine, C-reactive protein and Troponin T were measured using Cobas ® 6000 (Roche Diagnostics, Indianapolis, USA). Lactate was measured using ABL800 FLEX (Radiometer, Brønshøj, Denmark).
| Laboratory investigations
Levels of the LP proteins (mannan-binding lectin (MBL), 22 were analysed using time-resolved immunofluorometric assays (TRIFMA ® ). Detailed descriptions of the assays are found in the reference given for each protein. [21] [22] [23] [24] [25] [26] [27] In brief, Fluoronunc microtiter plates (NUNC ® , Denmark) were coated with specific anti-LP protein antibodies (or the polysaccharide mannan in case of quantifying mannanbinding lectin). Diluted standards, controls and samples were added in duplicate using a JANUS ® Automated
Workstation (PerkinElmer ® , Hamburg, Germany). The plates were hereafter incubated with different biotinylated antibodies and later europium-labelled streptavidin. An enhancement buffer was added to resolve europium from the biotin-streptavidin complex. To quantify protein concentrations, the plates were read by a VICTOR ™ X5
reader (PerkinElmer ® , Hamburg, Germany). Three internal controls were applied on all plates. The inter-assay coefficient of variation was below 15% for all assays except MASP-2 (control 1: 4.5%, control 2: 6.7% and control 3: 20.6%) and H-ficolin (control 1: 15.7%, control 2: 12.6% and control 3: 17.9%).
| Statistics
The sample size calculation estimated the sample size needed to investigate whether the duration of targeted temperature management influenced the levels of LP proteins. It was based on MASP-2 levels in a population of Danish blood donors. 21 The mean MASP-2 level was 534 ng/mL with a standard deviation at ±213 ng/mL. With 40 patients in each group, a significance level (2α) at 0.05 and a test power (1-β) at 90%, we would be able to find a difference of 156 ng/mL or more in MASP-2. Patient characteristics and prehospital variables following Gaussian distribution are presented as mean with standard deviation or as numbers with proportions (%), and variables not following Gaussian distribution are presented as median and lower and upper quartile. Data were assessed for Gaussian distribution by QQ-plots and F-tests. An unpaired t test was performed when comparing the 22-hour samples with samples from healthy individuals if Gaussian distribution was followed, and a Wilcoxon ranksum test if Gaussian distribution was not followed. Similar procedure was performed when comparing levels of LP proteins after 22 hours in survivors vs non-survivors 30 days after cardiac arrest, and when comparing laboratory characteristics between patients treated with standard or prolonged duration of targeted temperature management. To compare differences in plasma concentrations between groups over time, a mixed model of repeated measurements was used. Statistics were performed in Stata13 ® (StataCorp, Texas, USA). Graphics were done in Graphpad Prism version 6 (GRAPHPAD Software, California, USA). All tests were two-sided, and P-values < 0.05 were considered statistically significant.
| RESULTS
| Patient characteristics
A total of 82 patients resuscitated after out-of-hospital cardiac arrest were included. Among these, 42 patients received standard (24 hours) and 40 patients received prolonged (48 hours) duration of targeted temperature management. The main cause of the cardiac arrest was an acute coronary syndrome or an arrhythmia. The majority (73%) were cooled by intravascular cooling. Detailed demographics and clinical characteristics, including comorbidities and prehospital data are shown in Table 1 .
Results of routine biochemistry blood samples are presented in Table 2 .
| LP proteins in healthy individuals vs cardiac arrest patients
Plasma concentrations of CL-L1 (P = .03), MASP-1 (P = .02), MASP-2 (P = .01) and MAp44 (P = .03) were significantly higher in cardiac arrest patients compared with healthy individuals. Levels of M-ficolin (P = .01) were significantly lower in cardiac arrest patients, whereas for Hficolin, MBL and MASP-3 no statistically significant differences were found between cardiac arrest patients and healthy individuals (Figure 2 ).
| LP proteins in standard vs prolonged targeted temperature management
There were no differences in the LP protein levels between the standard and the prolonged groups in the 22-hour sample. Compared with the standard group, a significantly 
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Levels of lectin pathway proteins in 82 cardiac arrest patients at the 22-h sample and in 82 healthy individuals. Bars indicate median, lower and upper quartile. An unpaired t test was performed if Gaussian distribution was followed, and a Wilcoxon rank-sum test if Gaussian distribution was not followed higher level of MASP-3 was found in the prolonged group at 46 hours (21% (95% confidence interval (CI): 4%-41%)) and at 70 hours (67% (95% CI: 43%-95%)). For M-ficolin, a significantly lower level (26% (95% CI: 12%-38%)) was found in the prolonged group at 46 hours, whereas for MASP-2 a significant higher level (23% (95% CI: 1%-51%)) was found in the prolonged group at 46 hours. For the remaining proteins, no statistically significant differences were found between the standard and the prolonged groups (Figure 3 ).
| Development of the LP protein level
within groups over a period of time From 22 hours to 46 hours, we found that plasma concentrations of MASP-3, CL-L1, H-ficolin and MAp44 significantly increased, while MASP-1 decreased in the standard group. Regarding the prolonged group levels of CL-L1, Hficolin, MASP-2 and MASP-3 increased significantly, while M-ficolin decreased.
From 46 hours to 70 hours, we found that MAp44 levels increased and levels of M-ficolin and MASP-3 decreased in the standard group. With regard to the prolonged grouped, we observed an increase in the levels of M-ficolin, MASP-3 and MAp44, while a significant decrease was found in Hficolin levels. For MBL no significant differences in levels were seen at any time for both groups.
To investigate differences in concentrations of the LP proteins between 30-day survivors (57 patients) and nonsurvivors (25 patients) after cardiac arrest, the study population was divided into 30-day survivors and non-survivors. We found no significant concentration differences between 30-day survivors and non-survivors in any proteins when testing the initial sample (22 hours).
| DISCUSSION
The levels of several LP proteins (CL-L1, MASP-1, MASP-2 and MAp44) were significantly higher in cardiac arrest patients compared with healthy individuals. We found no clear pattern in the changes of LP proteins during the initial 70 hours post-cardiac arrest, and overall the duration of targeted temperature management did not systematically influence the level of these proteins. There was no difference in the LP protein levels between 30-day survivors and non-survivors in the 22-hour samples, indicating that LP protein levels are not associated with 30-day mortality after cardiac arrest.
The LP is initiated by binding of the pattern recognition molecules (MBL, CL-L1, M-and H-ficolin) to apoptotic or necrotic cells, which confers the activation of the initiating enzymes (MASPs). 11 The ischemic condition during cardiac arrest mediates the formation of neo-epitopes, detectable for complement proteins. 28 Exposure of neo-epitopes in complement activation upon reperfusion is central in initiating cell injury. 29 Additionally, reperfusion mediates the formation of reactive oxygen species leading to further cell damage. A relationship between oxidative stress, expression of neo-epitopes and subsequent activation of complement proteins has been suggested. 12 In the present study, CL-L1, MASP-1 and MASP-2 levels were significantly higher in cardiac arrest patients compared with healthy individuals. This can lead to the assertion that cardiac arrest patients have a more activated LP compared with healthy individuals. However, whether higher levels of these proteins correspond to a more activated complement system is unknown. Lower levels could also be due to the consumption of LP proteins during complement activation, a known phenomenon seen in other complement proteins. 30 Levels of MBL, M-ficolin, H-ficolin and MASP-2 have shown large variation between healthy adults. 31 Moreover, levels of several LP proteins have shown significant gender differences, but do not seem to change much with age in healthy individuals. 21 Therefore, the cardiac arrest patients and healthy individuals were matched by gender in the present study. MBL deficiency (≤100 ng/mL in plasma) occurs in approximately 10% of the Caucasian population, 31 which was also reflected in the cardiac arrest patients and healthy individuals in this study. MAp44 and MBL have previously been measured in cardiac arrest patients. 17 In accordance with the present study, Bro-Jeppesen et al 17 found that the levels of MBL and
MAp44 were not associated with 30-day mortality. Bro-Jeppesen et al 17 found that levels of MBL and MAp44 increased significantly within 72 hours compared with baseline. In the present study, MAp44 levels increased significantly when comparing the levels at 70 hours with the levels at 22 hours, but levels of MBL did not change significantly. Targeted temperature management is suggested to reduce complement activation. 10, 14 We found higher levels of MASP-2 and MASP-3 and lower levels of M-ficolin in the prolonged group compared with the standard group. As the higher level of MASPs may indicate a higher capacity for increased activation of the complement system, these changes may attenuate the expected advantage of prolonged hypothermia. Lectin pathway activation leads to the formation of opsonins (C3b), anafylatoxins (C3a and C5a) and the cytolytic membrane attack complex (MAC or C5b9), which carry out crucial immunological effector functions of the complement system. 11 Bisschops et al 32 observed that rewarming after cardiac arrest was followed by increasing levels of inflammation products, including C3a and MAC. Furthermore, Jenei et al 14 found that a higher C3a/C3 ratio, a measure of complement activity, was associated with 6 of 9 | F I G U R E 3 Levels of lectin pathway proteins (ng/mL) in patients treated with standard duration (n = 42) compared with prolonged duration (n = 40) of targeted temperature management. A mixed model of repeated measurements was used to achieve the results. Significant difference between groups is marked by *. Differences was found for MASP-2 (P = .04), MASP-3 (P = .01 (46-h sample) and P = .01 (70-h sample)) and M-ficolin (P = .01). Bars indicate median, lower and upper quartile poor survival. In the present study, we found that rewarming was followed by significant increases in MASP-3 levels ( Figure 3) . However, MASP-3 levels did not seem to be associated with 30-day mortality after cardiac arrest. To our knowledge, the present study was the first to measure LP proteins CL-L1, M-ficolin, H-ficolin, MASP-1, MASP-2 and MASP-3 in cardiac arrest patients. In order to investigate how the LP influences the pathogenesis of the post-cardiac arrest syndrome and to clarify how this pathway affects cardiac arrest patients, it is pivotal to investigate numerous proteins of this pathway.
We expect the classical and the alternative pathway to contribute to the formation of common pathway components in post-cardiac arrest syndrome; however, the extent is still unknown. A previous animal study has demonstrated that all 3 initiating pathways were activated after cardiac arrest, 33 but from the LP Gong et al 33 only included MBL.
Thus, the complement system may play an important role in exacerbating the damage after cardiac arrest, and therefore, studies to target complement system proteins should be of future interest. A limitation of this study was the lack of a blood sample for the determination of LP proteins upon admission. Thereby, there is a risk that not only the post-cardiac arrest syndrome affects the level of the LP proteins but also, e.g, invasive procedures performed after admission. Thus, the differences found between healthy individuals and the sample obtained after 22 hours may be caused by other factors than the cardiac arrest. However, the extent of invasive procedures would probably be distributed equally between the 2 treatment groups. Another limitation was the small sample size increasing the risk of type-2 errors, in particular in the mortality comparison, where the present study might be considered as a pilot study. Furthermore, the analysis of proteins reflecting the downstream effects of LP complement activation, ie, activation products of the complement system, would have added further information to the significance of the findings.
In conclusion, we found that the levels of LP proteins CL-L1, MASP-1, MASP-2 and MAp44 were significantly higher, and M-ficolin levels were significantly lower in cardiac arrest patients compared with healthy individuals. This may indicate that cardiac arrest patients have a more activated LP compared with healthy individuals. Overall, LP protein levels were not systematically influenced by the duration of targeted temperature management. Protein levels at 22 hours were not associated with 30-day survival after cardiac arrest.
ACKNOWLEDGMENT
The present study was funded by Aarhus University and Helga and Peter Kornings Foundation. The authors would like to thank Annette G. Hansen and Lisbeth Jensen for skilful laboratory assistance.
